CCC
ARKG icon

Crescent Capital Consulting’s ARK Genomic Revolution ETF ARKG Stock Holding History

Crescent Capital Consulting’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-100
Closed -$9K – 506
2020
Q4 		$9K Buy
+100
New +$7.97K ﹤0.01% 355

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SDH
Sloy Dahl & Holst Vancouver, Washington $728M AUM 37.66% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Crescent Capital Consulting's ARKG Position: Q1 2021 in Review

Crescent Capital Consulting sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2021, closing a stake of 100 shares — an estimated $9K sold.

Crescent Capital Consulting first reported a position in ARKG in Q4 2020 and held it in 1 quarter. The position peaked at $9K in Q4 2020. 505 funds tracked by Wall St. Rank hold ARKG as of Q1 2021.

  • Crescent Capital Consulting reported no remaining ARK Genomic Revolution ETF position as of Q1 2021 after selling out during the quarter.
  • Crescent Capital Consulting sold 100 ARK Genomic Revolution ETF shares in Q1 2021, an estimated $9K.
  • Crescent Capital Consulting first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 1 quarter.
  • Crescent Capital Consulting's ARK Genomic Revolution ETF position peaked at $9K in Q4 2020.
  • 505 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2021.

Based on Crescent Capital Consulting's 13F filing for Q1 2021, filed 15 Apr 2021.